These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36399537)

  • 1. Prognostic Value of 18F-Fluorodeoxyglucose-Positron Emission Tomography/Magnetic Resonance Imaging in Patients With Hypopharyngeal Squamous Cell Carcinoma.
    Huang C; Zhang L; Meng Z; Song T; Mukherji SK; Chen X; Lu J; Xian J
    J Comput Assist Tomogr; 2022 Nov-Dec 01; 46(6):968-977. PubMed ID: 36399537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between apparent diffusion coefficients and metabolic parameters in hypopharyngeal squamous cell carcinoma: A prospective study with integrated PET/MRI.
    Zhang L; Song T; Meng Z; Huang C; Chen X; Lu J; Xian J
    Eur J Radiol; 2020 Aug; 129():109070. PubMed ID: 32454330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PET/MRI in Cervical Cancer: Associations Between Imaging Biomarkers and Tumor Stage, Disease Progression, and Overall Survival.
    Shih IL; Yen RF; Chen CA; Cheng WF; Chen BB; Chang YH; Cheng MF; Shih TT
    J Magn Reson Imaging; 2021 Jan; 53(1):305-318. PubMed ID: 32798280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of 18F-FDG PET/MRI in patients with advanced oropharyngeal and hypopharyngeal squamous cell carcinoma.
    Pace L; Nicolai E; Cavaliere C; Basso L; Garbino N; Spinato G; Salvatore M
    Ann Nucl Med; 2021 Apr; 35(4):479-484. PubMed ID: 33575927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer.
    Miccò M; Vargas HA; Burger IA; Kollmeier MA; Goldman DA; Park KJ; Abu-Rustum NR; Hricak H; Sala E
    Eur J Radiol; 2014 Jul; 83(7):1169-1176. PubMed ID: 24767630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET/MRI in Endometrial Cancer: Imaging Biomarkers are Associated with Disease Progression and Overall Survival.
    Shih IL; Yen RF; Chen CA; Cheng WF; Chen BB; Zheng QY; Cheng MF; Chen JL; Shih TT
    Acad Radiol; 2024 Mar; 31(3):939-950. PubMed ID: 37714718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of
    Yu CW; Chen XJ; Lin YH; Tseng YH; Lu CC; Chen BB; Wei SY; Lee JM; Shih TT
    Eur J Radiol; 2019 Nov; 120():108671. PubMed ID: 31629121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative parameters derived from
    Meng Z; Zhang L; Huang C; Piao Y; Chen X; Xian J
    Neuroradiology; 2022 Nov; 64(11):2153-2162. PubMed ID: 36121469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
    Hwang SH; Cho A; Yun M; Choi YD; Rha SY; Kang WJ
    Clin Nucl Med; 2017 May; 42(5):e235-e241. PubMed ID: 28288043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prognostic value of pretreatment (18)F-FDG PET-CT for patients with advanced diffuse large B-cell lymphoma].
    Ding CY; Guo Z; Sun J; Yang WP; Li TR
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):528-533. PubMed ID: 30060362
    [No Abstract]   [Full Text] [Related]  

  • 11. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 12. Prediction of tumour grade and survival outcome using pre-treatment PET- and MRI-derived imaging features in patients with resectable pancreatic ductal adenocarcinoma.
    Dunet V; Halkic N; Sempoux C; Demartines N; Montemurro M; Prior JO; Schmidt S
    Eur Radiol; 2021 Feb; 31(2):992-1001. PubMed ID: 32851447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic value of combined MTV and ADC derived from baseline FDG PET/MRI in aggressive non-Hodgkins lymphoma.
    Husby T; Johansen H; Bogsrud TV; Hustad KV; Evensen BV; Boellaard R; Giskeødegård GF; Fagerli UM; Eikenes L
    BMC Cancer; 2022 Nov; 22(1):1117. PubMed ID: 36319985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Whole body FDG PET/MR for progression free and overall survival prediction in patients with relapsed/refractory large B-cell lymphomas undergoing CAR T-cell therapy.
    Sjöholm T; Korenyushkin A; Gammelgård G; Sarén T; Lövgren T; Loskog A; Essand M; Kullberg J; Enblad G; Ahlström H
    Cancer Imaging; 2022 Dec; 22(1):76. PubMed ID: 36575477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer.
    Liao S; Penney BC; Wroblewski K; Zhang H; Simon CA; Kampalath R; Shih MC; Shimada N; Chen S; Salgia R; Appelbaum DE; Suzuki K; Chen CT; Pu Y
    Eur J Nucl Med Mol Imaging; 2012 Jan; 39(1):27-38. PubMed ID: 21946983
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic value of baseline [18F]-fluorodeoxyglucose positron emission tomography parameters MTV, TLG and asphericity in an international multicenter cohort of nasopharyngeal carcinoma patients.
    Zschaeck S; Li Y; Lin Q; Beck M; Amthauer H; Bauersachs L; Hajiyianni M; Rogasch J; Ehrhardt VH; Kalinauskaite G; Weingärtner J; Hartmann V; van den Hoff J; Budach V; Stromberger C; Hofheinz F
    PLoS One; 2020; 15(7):e0236841. PubMed ID: 32730364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma.
    Zhou M; Chen Y; Huang H; Zhou X; Liu J; Huang G
    Oncotarget; 2016 Dec; 7(50):83544-83553. PubMed ID: 27835875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Confirmation of the prognostic value of pretherapeutic tumor SUR and MTV in patients with esophageal squamous cell carcinoma.
    Hofheinz F; Li Y; Steffen IG; Lin Q; Lili C; Hua W; van den Hoff J; Zschaeck S
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1485-1494. PubMed ID: 30949816
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining standardized uptake value of FDG-PET and apparent diffusion coefficient of DW-MRI improves risk stratification in head and neck squamous cell carcinoma.
    Preda L; Conte G; Bonello L; Giannitto C; Travaini LL; Raimondi S; Summers PE; Mohssen A; Alterio D; Cossu Rocca M; Grana C; Ruju F; Bellomi M
    Eur Radiol; 2016 Dec; 26(12):4432-4441. PubMed ID: 26965504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.